
Apax and 3i enter exclusive talks over Azelis
Apax Partners has entered into exclusive negotiations to acquire 3i’s majority stake in Azelis, a Belgium-based speciality chemicals distributor.
The proposed deal, which is subject to antitrust approval, comes around two years after 3i took part in a €30m capital increase for Azelis.
3i acquired the company for €315m in 2007. Since then, it has undertaken an international growth strategy involving the hire of new senior management and the sale of its composite business to German trade player Velox.
Azelis has recently opened a new office in Chengdu, west China, and a new laboratory facility in Hertford, UK. It has also signed a distribution deal with renewable chemicals company Myriant in recent months.
In 2011, 3i was rumoured to be auctioning off the business, reportedly hiring Bank of America Merrill Lynch to run the process.
Antwerp-based Azelis was founded in 2001 through the merger of Novorchem in Italy and Arnaud in France.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater